Proteasome subunit, Enzyme complex component (19S regulatory particle of the 26S proteasome), Chaperone (for proteasome assembly)
01
Overview
26S proteasome non-ATPase regulatory subunit 9 (PSMD9) is a non-ATPase component of the 19S regulatory particle of the 26S proteasome, a large multi-subunit enzyme complex essential for ATP/ubiquitin-dependent degradation of intracellular proteins. PSMD9 functions as an assembly chaperone for the 19S base subcomplex and is released during later stages of assembly. Emerging evidence indicates roles for PSMD9 in protein quality control, transcriptional regulation via interactions mediated by its PDZ-like domain, mRNA processing, response to cellular stress, protein translation, and potentially linking the proteasome with the unfolded protein response and protein synthesis networks. Dysfunction or altered expression of PSMD9 has been implicated in several human diseases, including certain cancers, neurodegenerative, and metabolic disorders.
For general proteasome inhibitors: Inhibition of proteasome-mediated protein degradation, leading to accumulation of ubiquitinated proteins, cell cycle arrest, and apoptosis, particularly in rapidly dividing cells such as in certain cancers
03
Biological functions
Protein degradation (ATP/ubiquitin-dependent, non-lysosomal pathway)Protein quality controlImmunoproteasome function (processing of class I MHC peptides)Transcriptional regulation (through protein interactions)mRNA processing and editingHormone and receptor regulationProtein translationUnfolded protein response (UPR)
04
Disease associations
Cancer (implicated via ubiquitin-proteasome pathway and potential roles in NF-κB and p53 regulation)Neurodegenerative disease (proteasome dysfunction linked)Metabolic diseases (e.g., maturity-onset diabetes of the young, type 3; mononeuropathy of the median nerve)Alzheimer’s disease pathway association
05
Safety considerations
Targeting the proteasome, especially non-ATPase subunits such as PSMD9, could disrupt general protein degradation and homeostasis, leading to accumulation of damaged or misfolded proteins and widespread cellular dysfunctionAdverse effects of systemic proteasome inhibition include neurotoxicity, immunosuppression, and risk of infection (based on proteasome inhibitor class effects)
06
Interacting drugs
No direct small molecule inhibitors or modulators specifically targeting PSMD9 are described in current references. General proteasome inhibitors (e.g., bortezomib, carfilzomib) act on the 26S complex but not specifically on PSMD9
07
Biomarkers
No direct, validated clinical biomarkers specifically for PSMD9 currently in use, but global proteasome activity, subunit composition, or defects can serve as proxies in research or some diagnostics
Beyond the preview
Go deeper on 26S proteasome non-ATPase regulatory subunit 9 (PSMD9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on 26S proteasome non-ATPase regulatory subunit 9 (PSMD9).